Endotronix Presents Results of Cordella PA Pressure Sensor System in (SIRONA 2) for NYHA Class III Heart Failure at ESC 2022
Shots:
- The (SIRONA 2) trial evaluates Cordella PA pressure sensor system in 70 NYHA class III HF patients at 7 EU sites across Ireland, Belgium & Germany
- The trial met primary safety & efficacy EPs i.e., low rates of HF hospitalization @3 & 6mos., good safety outcome without any PA sensor failures & 0% mortality @90 days, equivalent accuracy of PA pressure measurement over gold standard fluid-filled reference catheter, 65.7% improved NYHA classification @90 days
- 84% preferred reading PA pressure in a seated position instead of lying flat, the system was easy to use (94%) & patient compliance with daily measurements (93%) @180 days. The system without the sensor is commercially available in the US & the EU and is in use in cardiology centers across the US
Ref: PR Newswire | Image: Endotronix
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
